Servier India introduces‘Ivosidenib’ (Tibsovo®),in India, First-in-classTargetedTherapy in Oncologyfor Rare IDH1-Mutated AML and Cholangiocarcinoma
2025-Servier India, a subsidiary of the leading French pharmaceutical Servier Group, announced the launch ofIvosidenib (Tibsovo®), an oral targeted therapy approved in the management of cancer patients with Acute Myeloid Leukemia (AML) and Cholangiocarcinoma,with an isocitrate dehydrogenase-1 (IDH1) mutation. Servier India received the approval on 14th May 2025, from Central Drugs Standard Control Organisation (CDSCO)…